PURPOSE: Vaccination against human cancer is a promising therapeutic approach but the optimal antigen or antigens remain undefined. Cancer-testis antigens (CTA), a family of tumor-associated antigens, have both potent immunogenicity and restricted expression patterns in normal adult tissues, highly desirable characteristics for targets of anticancer vaccines. These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium. EXPERIMENTAL DESIGN: The expression patterns of nine CTAs (NY-ESO-1, LAGE-1, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, CT7, CT10, and GAGE) were examined by immunohistochemistry and reverse transcription-PCR in a panel of high-grade urothelial carcinomas of the urinary bladder. Also assessed were correlations between the expression of CTAs by immunohistochemistry and both disease-free and overall survival. RESULTS: At least one CTA was expressed in 77% of samples and 61% of these tumors expressed more than one CTA. Additionally, patients with CT10-positive tumors had an improved disease-free survival (P=0.008) and overall survival (P=0.037) compared with patients with CT10-negative tumors. CONCLUSIONS: These findings establish CTAs as potential prognostic markers and as target candidates for vaccine development for patients with urothelial carcinoma.
PURPOSE: Vaccination against humancancer is a promising therapeutic approach but the optimal antigen or antigens remain undefined. Cancer-testis antigens (CTA), a family of tumor-associated antigens, have both potent immunogenicity and restricted expression patterns in normal adult tissues, highly desirable characteristics for targets of anticancer vaccines. These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium. EXPERIMENTAL DESIGN: The expression patterns of nine CTAs (NY-ESO-1, LAGE-1, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, CT7, CT10, and GAGE) were examined by immunohistochemistry and reverse transcription-PCR in a panel of high-grade urothelial carcinomas of the urinary bladder. Also assessed were correlations between the expression of CTAs by immunohistochemistry and both disease-free and overall survival. RESULTS: At least one CTA was expressed in 77% of samples and 61% of these tumors expressed more than one CTA. Additionally, patients with CT10-positive tumors had an improved disease-free survival (P=0.008) and overall survival (P=0.037) compared with patients with CT10-negative tumors. CONCLUSIONS: These findings establish CTAs as potential prognostic markers and as target candidates for vaccine development for patients with urothelial carcinoma.
Authors: Padmanee Sharma; Yu Shen; Sijin Wen; Sachiko Yamada; Achim A Jungbluth; Sacha Gnjatic; Dean F Bajorin; Victor E Reuter; Harry Herr; Lloyd J Old; Eiichi Sato Journal: Proc Natl Acad Sci U S A Date: 2007-02-27 Impact factor: 11.205
Authors: Ivan V Litvinov; Brendan Cordeiro; Yuanshen Huang; Hanieh Zargham; Kevin Pehr; Marc-André Doré; Martin Gilbert; Youwen Zhou; Thomas S Kupper; Denis Sasseville Journal: Clin Cancer Res Date: 2014-05-21 Impact factor: 12.531
Authors: Evelyne Lerut; Hendrik Van Poppel; Steven Joniau; Olivier Gruselle; Thierry Coche; Patrick Therasse Journal: Int J Clin Exp Pathol Date: 2015-08-01
Authors: Otavia L Caballero; Qi Zhao; Donata Rimoldi; Brian J Stevenson; Suzanne Svobodová; Sylvie Devalle; Ute F Röhrig; Anna Pagotto; Olivier Michielin; Daniel Speiser; Jedd D Wolchok; Cailian Liu; Tanja Pejovic; Kunle Odunsi; Francis Brasseur; Benoit J Van den Eynde; Lloyd J Old; Xin Lu; Jonathan Cebon; Robert L Strausberg; Andrew J Simpson Journal: PLoS One Date: 2010-09-16 Impact factor: 3.240